Boehringer Ingelheim Reports the Acquisition of Nerio Therapeutics for $1.3B
Shots:
- Boehringer Ingelheim has acquired Nerio Therapeutics for up to $1.3B, to strengthen its immuno-oncology pipeline
- The acquisition adds Nerio Therapeutics’ preclinical program to Boehringer Ingelheim. The company will further develop the program to treat cancer patients
- Nerio’s small molecules target the protein tyrosine phosphatases N1 and N2 (PTPN1 & PTPN2), which can activate the immune system to combat cancer cells
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
